home / stock / pcsa / pcsa short
Short Information | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 15,508 |
Total Actual Volume | 22,719 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 14 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 775 |
Average Short Percentage | 67.47% |
Is there a PCSA Short Squeeze or Breakout about to happen?
See the PCSA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-23-2020 | $9.99 | $9.94 | $9.99 | $9.74 | 800 | 800 | 100% |
09-22-2020 | $10.1 | $10.1 | $11 | $10.1 | 2,100 | 900 | 42.86% |
09-21-2020 | $8.19 | $9.39 | $9.39 | $8.19 | 2,280 | 2,280 | 100% |
09-18-2020 | $8.19 | $8.39 | $8.39 | $8.19 | 1,600 | 1,600 | 100% |
09-17-2020 | $8 | $8 | $8 | $7.805 | 1,500 | 1,076 | 71.73% |
09-16-2020 | $8.45 | $8.05 | $8.45 | $8.05 | 1,000 | 500 | 50% |
09-14-2020 | $8 | $8.45 | $8.45 | $8 | 1,814 | 820 | 45.2% |
09-08-2020 | $7.7 | $7.6 | $7.7 | $7.6 | 200 | 100 | 50% |
09-03-2020 | $8 | $8 | $8 | $8 | 184 | 180 | 97.83% |
09-02-2020 | $7.95 | $7.95 | $7.95 | $7.95 | 1,050 | 1,000 | 95.24% |
09-01-2020 | $7.9 | $7.9 | $8 | $7.9 | 302 | 2 | 0.66% |
08-27-2020 | $8.15 | $8.25 | $8.25 | $8.15 | 200 | 100 | 50% |
08-21-2020 | $8.19 | $8.19 | $8.19 | $8.19 | 250 | 150 | 60% |
07-22-2020 | $8.5 | $8.5 | $8.5 | $8.5 | 900 | 900 | 100% |
07-17-2020 | $8 | $8 | $8 | $8 | 200 | 200 | 100% |
07-16-2020 | $7 | $8 | $8 | $7 | 805 | 400 | 49.69% |
07-13-2020 | $6.71 | $6.5 | $6.71 | $6.255 | 4,300 | 2,800 | 65.12% |
06-09-2020 | $6.5 | $7 | $7 | $6 | 1,286 | 300 | 23.33% |
05-29-2020 | $8 | $8 | $8 | $8 | 900 | 900 | 100% |
05-13-2020 | $8.01 | $6.0001 | $8.01 | $6.0001 | 1,048 | 500 | 47.71% |
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...